Table 2.
Potential methods to predict and/or assess response to IL-23 inhibition
| Biomarker/predictor | Observed pattern[s] |
|---|---|
| Patient-based factors | • Higher induction dosing of risankizumab was associated with higher rates of endoscopic response/remission during maintenance therapy in patients with CD13 • Biologic-naïve UC patients had numerically higher rates of clinical remission with mirikizumab compared with patients with prior biologic exposure [though not statistically significant]17 • Biologic-naïve CD patients had numerically higher rates of clinical remission and endoscopic response with risankizumab compared with patients with prior biologic exposure [though not statistically significant]15 • CD patients with endoscopic and/or clinical response or remission following induction therapy with mirikizumab were more likely to have sustained response at Week 5218 |
| TNFR2+IL23+ T cells | • Patients with TNFR2+IL23+ T cells were significantly less likely to respond to anti-TNF therapy25 |
| IL-22 following therapy | • IL-22 levels decreased following mirikizumab induction therapy for treatment of UC17 • IL-22 gene expression in ileal tissue decreased following rizankizumab induction therapy for treatment of CD13 • IL-22 levels decreased following brazikumab induction therapy for treatment of CD16 • IL-22 levels remained suppressed after withdrawal of guselkumab therapy in psoriasis patients with sustained clinical response; IL-22 levels increased following recurrence of symptoms26 |
| IL-17 following therapy | • IL-17 levels decreased with mirikizumab induction therapy for treatment of UC17 • IL-17A and IL17F levels remained suppressed after withdrawal of guselkumab therapy in psoriasis patients with sustained clinical response; IL-17A and IL-17F levels increased following recurrence of symptoms26 |
| IL-22 prior to therapy | • Patients with IL-22 levels greater than the median threshold of 15.6 pg/mL were significantly more likely to achieve clinical response and remission following brazikumab induction therapy for treatment of CD16 • Patients with elevated IL-22 levels at baseline were significantly more likely to respond to direct IL-22 inhibition with fezakinumab for treatment of atopic dermatitis27 |
CD, Crohn’s disease; UC, ulcerative colitis.